- February 07, 2020
Madam Speaker, siblings Callum and Aislinn Stepaniuk of St. Albert, ages seven and 12, have cystic fibrosis carrying the R117H mutation. Due to a lack of approvals, they are unable to receive the life-extending drug Kalydeco. Every day that they cannot access this drug shortens their life expectancy.
Why should Callum and Aislinn have to wait, given that the U.S. FDA has approved this drug for children with this mutation who are six years and older?